Source: PharmaLive
Area: News
According to a report by PharmaLive, the European Commission has approved a new indication for ranibizumab (Lucentis®) - to treat patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO and central RVO). Ranibizumab is the first anti-VEGF (vascular endothelial growth factor) therapy to be licensed for this indication in the EU.
RVO results from a blockage forming in a blood vessel in the retina. In CRVO, the blockage occurs in the main retinal vein at the optic nerve, whereas (Read more...)
Uncategorized